La dégénérescence maculaire liée à l'âge érode la vision centrale que vous utilisez pour lire et reconnaître les visages. La vision périphérique qui vous sert à vous déplacer est en général préservée, si bien qu'elle ne prend pas toute votre vue. Perdre le centre est invalidant en soi. Il existe deux formes.
La forme sèche est fréquente et lente. La forme humide est moins fréquente, plus rapide, et c'est celle qui nécessite un traitement urgent. La chose la plus puissante à votre portée est de ne pas fumer, ce qui abaisse votre risque de maladie avancée plus que tout ce que vous pouvez faire d'autre. Pour les personnes qui présentent déjà une maladie intermédiaire, la formule AREDS2 ralentit la progression vers la maladie avancée, même si elle ne prévient pas la maladie précoce.
Practice Ranking
Every practice we track for Macular Degeneration: What Protects Your Sight, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
4 practices · 3 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Quitting Smoking: What It Does to the Body and the Methods That Actually Work The leading modifiable risk factor for AMD. | Strong | Pro | Free to $$ | Hard | Days to Longer | |
| 2 | The Mediterranean Diet: What It Does, Why It Works, and How to Start Closest Mediterranean-diet adherence tracked with far less advanced AMD; the most empowering everyday lever, on observational evidence. | Moderate | Self-Directed | $ to $$ | Moderate | Months to Longer | |
| 3 | Whole Foods and Ultra-Processed Foods: What the Evidence Shows and How to Eat Well Leafy greens and other carotenoid-rich vegetables tracked with less advanced AMD, feeding the same pigments the eye concentrates in the macula. | Moderate | Self-Directed | $ to $$ | Moderate to Hard | Weeks to Months | |
| 4 | Omega-3 and Fish Oil: Clear on Triglycerides, Mixed on the Heart Despite the theory, adding omega-3 to the eye formula did not slow progression to advanced AMD, so do not rely on fish oil here. | Strong | Supplement | $ to $$ | Easy | Weeks to Months | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Age-related macular degeneration damages the macula, the small central patch of retina that carries fine detail. It takes reading, faces, and the center of a scene first. There are two forms. The dry form is the common, slow kind: yellow deposits called drusen collect beneath the central retina, and the light-sensing cells thin. Most people at this early stage hold useful vision for years, and many never progress. The advanced dry stage, geographic atrophy, is patches where central cells have died, leaving blind spots that widen slowly. The dry form can turn wet at any stage: abnormal new vessels grow beneath the macula, and central vision can blur over days to weeks.
What Helps
Most of what protects the macula is not a supplement. Not smoking is the one strongest lever. No food or supplement reduces advanced-disease risk as much, and the risk keeps falling in the years after you quit.
Diet comes next. People who keep closest to a Mediterranean-style plate, and who eat the most leafy greens, develop less advanced disease. Spinach and collard greens carry the most weight, because they are the richest food source of lutein and zeaxanthin.
The AREDS2 supplement helps a narrow group: people whose disease is already intermediate, or advanced in one eye. For them it cuts the risk of progressing to advanced disease by about a quarter over six years, a relative reduction. It does nothing for healthy eyes or early changes. The formula comes in a lutein-and-zeaxanthin version.
For the wet form, a specialist injects anti-VEGF drugs into the eye. For geographic atrophy, a newer class of complement-inhibitor injections slows the patch's growth on retinal scans. So far the scans improve but eyesight does not.
A sudden change in central vision can mean the dry form has turned wet. That is the moment to get a same-day retina review.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Vision
The antioxidant and zinc formula cut progression to advanced AMD by about 25% in intermediate disease
For people who already have moderate macular degeneration, a specific daily antioxidant and zinc supplement lowered the chance of it getting worse by about a quarter over six years, but it did nothing for people with healthy eyes or very early changes, and it cannot bring back lost sight.
In participants with intermediate AMD, or advanced AMD in one eye, a daily formula of vitamin C, vitamin E, beta-carotene and zinc (with copper) reduced the odds of progressing to advanced AMD by about 25% (odds ratio 0.72) and the risk of moderate vision loss by about 19% over a median 6.3 years. Participants with no AMD or only early AMD showed no benefit. Measured in: 3,640 people aged 55 to 80 with a range of AMD severity, randomized to antioxidants plus zinc, antioxidants alone, zinc alone, or placebo. The benefit was confined to those who already had intermediate AMD or advanced AMD in one eye; the formula did not slow anything in people with no AMD or early AMD, and it does not restore vision already lost. This original formula contained beta-carotene, later removed for the reasons in the safety claim.
Who this may not transfer to:Both sexes were enrolled across all AMD severity categories.
The study · 1
Age-Related Eye Disease Study Research Group, high-dose vitamins C and E, beta carotene and zinc for AMD and vision loss: AREDS report no. 8 · Arch Ophthalmol 2001;119(10):1417-36
Adding omega-3 to the formula did not slow progression to advanced AMD
Adding fish-oil (omega-3) to the eye supplement made no difference to whether macular degeneration got worse in the large AREDS2 trial.
Adding omega-3 fatty acids (350 mg DHA plus 650 mg EPA daily) to the AREDS formula produced no significant reduction in progression to advanced AMD compared with the formula without them (hazard ratio 0.97, not significant) over a median five years. Measured in: 4,203 people aged 50 to 85 at high risk of advanced AMD, in a factorial randomized trial. This was the isolated supplement measured against a hard clinical endpoint; oily fish eaten as food still fits the dietary pattern linked to lower risk, which is a separate line of evidence. The trial tested one dose and formulation of DHA and EPA.
Who this may not transfer to:Both sexes were enrolled; the null result applied across the trial population.
The study · 1
Age-Related Eye Disease Study 2 (AREDS2) Research Group, lutein + zeaxanthin and omega-3 fatty acids for AMD: the AREDS2 randomized clinical trial · JAMA 2013;309(19):2005-15
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Anti-VEGF injections kept vision in about 95% with wet AMD, against 62% on sham
For the wet form of macular degeneration, regular injections that block a growth signal called VEGF preserved vision in about 95% of people and let roughly a third regain some sight, provided treatment starts promptly.
In MARINA, monthly ranibizumab kept vision (fewer than 15 letters lost) in about 95% of people with neovascular AMD at one year against 62% on sham, and about 34% gained 15 or more letters against 5% on sham. In ANCHOR, ranibizumab maintained vision in about 94 to 96% against 64% on photodynamic therapy, with mean vision improving on treatment. Measured in: 716 people in MARINA (minimally classic or occult lesions) and 423 in ANCHOR (predominantly classic lesions), both randomized trials. The benefit depends on prompt and continued treatment, and the trial regimen was monthly injection; the injections carry a small risk of intraocular infection and are given by a specialist. They treat the wet form, not the dry.
Who this may not transfer to:Both trials enrolled men and women aged 50 and older with neovascular AMD.
The studies · 2
Rosenfeld PJ et al., ranibizumab for neovascular age-related macular degeneration (MARINA) · N Engl J Med 2006;355(14):1419-31
Brown DM et al., ranibizumab versus verteporfin for neovascular age-related macular degeneration (ANCHOR) · N Engl J Med 2006;355(14):1432-44
Le bévacizumab a égalé le ranibizumab pour la vision dans la DMLA humide, à une fraction du coût
The far cheaper drug bevacizumab worked about as well as the pricier ranibizumab for saving vision in wet macular degeneration.
À un an, le bévacizumab, bien moins coûteux, s'est révélé non inférieur au ranibizumab pour l'acuité visuelle dans la DMLA néovasculaire, avec des gains moyens de 8.0 contre 8.5 lettres (différence comprise dans la marge d'équivalence prédéfinie). Les taux de décès, d'infarctus du myocarde et d'AVC étaient similaires entre les deux médicaments, bien que les événements indésirables systémiques graves globaux (surtout des hospitalisations) aient été un peu plus fréquents avec le bévacizumab (24.1 % contre 19.0 % ; risque relatif 1.29, IC à 95 % 1.01 à 1.66), une différence que des analyses ultérieures n'ont pas confirmée de façon constante. Measured in: 1,208 people with neovascular AMD randomized to bevacizumab or ranibizumab, monthly or as-needed (CATT). Les deux médicaments étaient équivalents pour la vision, ce qui importe car le bévacizumab coûte une fraction du prix du ranibizumab ; l'essai a noté une petite différence dans certains événements graves non oculaires, que des analyses ultérieures n'ont pas confirmée de façon constante.
Who this may not transfer to:Both sexes were enrolled; results applied across the trial population.
The study · 1
Martin et al. 2011 (CATT, ranibizumab vs bevacizumab for neovascular AMD) · N Engl J Med 2011;364(20):1897-908
Lutein and zeaxanthin cut progression about 18% more than beta-carotene in the formula
Swapping beta-carotene for two natural eye pigments, lutein and zeaxanthin, worked at least as well at slowing macular degeneration and helped most in people who ate little of them, which is why the newer formula uses them.
In the direct comparison, replacing beta-carotene with lutein (10 mg) plus zeaxanthin (2 mg) was associated with an about 18% further reduction in progression to advanced AMD (hazard ratio 0.82, 95% CI 0.69 to 0.96), and the benefit was largest in participants whose dietary intake of these pigments was lowest. Measured in: Subgroup and secondary analyzes within the 4,203-participant AREDS2 trial. The overall primary comparison of adding lutein and zeaxanthin to the formula was not statistically significant; the 18% figure comes from the pre-specified secondary analysis directly substituting the pigments for beta-carotene, so it is supporting, not confirmatory evidence.
Who this may not transfer to:Both sexes were enrolled in AREDS2; the substitution analysis drew on the full trial.
The studies · 2
Chew et al. 2014 (AREDS2 report no. 3, secondary analyzes of lutein/zeaxanthin) · JAMA Ophthalmol 2014;132(2):142-9
Age-Related Eye Disease Study 2 (AREDS2) Research Group, lutein + zeaxanthin and omega-3 fatty acids for AMD: the AREDS2 randomized clinical trial · JAMA 2013;309(19):2005-15
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Current smokers carry about two to three times the risk of advanced AMD
Smoking is the biggest thing within your control that raises the risk of serious macular degeneration, roughly two to three times, and quitting brings the risk back down over time.
Pooling the observational evidence, current smoking was the most consistent modifiable risk factor for late AMD, with current smokers carrying roughly two to three times the risk of never-smokers, a clear dose-response with pack-years, and risk declining toward that of non-smokers over years after quitting. Measured in: Systematic reviews and meta-analyzes of population cohort and case-control studies of AMD risk factors. The underlying studies are observational, so residual confounding cannot be excluded, but the size, consistency and dose-response of the smoking association make it the strongest modifiable risk factor identified. The reviews report late AMD overall, not separating dry and wet cleanly.
Who this may not transfer to:The pooled cohorts and case-control studies included both sexes.
The studies · 2
Chakravarthy U et al., clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis · BMC Ophthalmol 2010;10:31
Thornton J et al., smoking and age-related macular degeneration: a review of association · Eye (Lond) 2005;19(9):935-44
Closest Mediterranean-diet adherence tracked with about 40% less advanced AMD
People who ate closest to a Mediterranean diet, more vegetables, fruit, fish, nuts and olive oil, were about 40% less likely to develop the advanced form of macular degeneration.
Pooling two long population cohorts, people in the highest tier of adherence to a Mediterranean diet had about 40% lower risk of developing incident advanced AMD than those in the lowest (hazard ratio around 0.59), with the association holding after adjustment for known risk factors. Measured in: 4,996 people in the Rotterdam Study (RS-I) and the Alienor Study, followed for incident advanced AMD (EYE-RISK Consortium). What could explain it instead: Healthy-user bias: people who eat closest to a Mediterranean pattern also tend to be less likely to smoke, more active and of higher socioeconomic status, all of which independently affect AMD risk. The analysis adjusted for measured factors but cannot remove unmeasured ones.. The association was with advanced AMD specifically, and the effect for early AMD was weaker. It is dietary-pattern evidence, not a trial, so it shows a consistent link, not proof that changing the diet changes the outcome.
Who this may not transfer to:Both cohorts enrolled men and women aged 55 and older.
The study · 1
Merle BMJ et al., Mediterranean diet and incidence of advanced age-related macular degeneration: the EYE-RISK Consortium · Ophthalmology 2019;126(3):381-90
The most carotenoid-rich vegetables tracked with about 43% less advanced AMD
People who ate the most carotenoid-rich vegetables, especially leafy greens like spinach, had roughly 40% to 50% lower risk of advanced macular degeneration.
People in the highest fifth of carotenoid intake had about 43% lower risk of advanced AMD than those in the lowest (odds ratio 0.57). Spinach and collard greens, rich in lutein and zeaxanthin, showed the strongest individual association, with the highest intake linked to roughly half the risk. Measured in: 356 people with advanced AMD and 520 controls in the multicenter Eye Disease Case-Control Study. What could explain it instead: Recall bias and healthy-diet clustering: people eating more leafy greens differ in other health behaviors, and diet was reported after diagnosis, which can color recall.. As a case-control study asking people what they ate, it is open to recall bias and cannot establish cause, but it is the classic finding that first pointed at the macular pigments and it agrees with the later dietary-pattern evidence.
Who this may not transfer to:Both sexes were included among cases and controls.
The study · 1
Seddon JM et al., dietary carotenoids, vitamins A, C, and E, and advanced AMD (Eye Disease Case-Control Study Group) · JAMA 1994;272(18):1413-20
Le pegcétacoplan a ralenti l'atrophie géographique sur les scans d'environ un cinquième, sans bénéfice sur la vision à deux ans
Un médicament injecté plus récent, le pegcétacoplan, a ralenti d'environ un cinquième la vitesse de croissance de la plage morte dans la dégénérescence maculaire sèche avancée observée sur les scans, mais il n'a pas amélioré ni protégé la vision dans les essais et a légèrement augmenté le risque de forme humide.
OAKS et DERBY étaient deux essais de phase 3 multicentriques, en double insu, contrôlés contre simulacre, incluant 1,258 personnes âgées de 60 ans et plus atteintes d'atrophie géographique liée à la DMLA, randomisées pour recevoir du pegcétacoplan intravitréen mensuellement, tous les deux mois, ou un simulacre. À 24 mois, le pegcétacoplan mensuel a ralenti la croissance de la lésion d'atrophie en autofluorescence du fond d'œil de 22 % dans OAKS (différence moyenne des moindres carrés -0.90 mm2, IC à 95 % -1.30 à -0.50) et de 19 % dans DERBY (-0.75 mm2, -1.15 à -0.34), le bras tous les deux mois suivant de près. Les critères secondaires clés de fonction visuelle, y compris l'acuité visuelle corrigée au mieux et la lecture fonctionnelle, n'ont montré aucune différence par rapport au simulacre à 24 mois. Une DMLA exsudative (humide) nouvellement apparue est survenue chez 11 % à 13 % des yeux sous injections mensuelles contre 2 % à 4 % sous simulacre. Ainsi, le médicament ralentit de manière fiable la progression structurelle sur laquelle il a été approuvé, tandis que son effet sur la vision qu'une personne utilise réellement n'est pas encore démontré.
Who this may not transfer to:Both trials enrolled men and women aged 60 and older with geographic atrophy from AMD; the effect was on the anatomical lesion, not on measured vision.
The study · 1
Heier JS et al., pegcetacoplan for geographic atrophy secondary to AMD (OAKS and DERBY): two phase 3 trials · Lancet 2023;402(10411):1434-48
How It Works
The macula is packed with two yellow pigments, lutein and zeaxanthin, pulled from food and concentrated there. They absorb short-wavelength light and mop up the reactive oxygen that constant light exposure produces. The antioxidants and zinc in the AREDS2 supplement target that same oxidative and metabolic stress on the retinal cells.
In the wet form, stressed retina releases vascular endothelial growth factor, or VEGF, which drives fragile new vessels to grow. Beneath the macula those vessels leak, and central vision blurs. Anti-VEGF drugs bind that signal, so the abnormal vessels shrink back and the leaking settles. Started early, these injections preserve vision for most people who receive them.
What the Research Argues Against
In the AREDS2 trial, adding omega-3 fish oil, the DHA and EPA, to the supplement formula did not slow progression to advanced disease. The isolated fatty acids made no difference to progression, even though a diet with oily fish is tied to lower risk.
Go Deeper
- Mediterranean diet: the eating pattern tied to less advanced disease.
- Omega-3 and fish oil: the capsule that failed the AREDS2 trial, and the food it comes from.
- Inflammation: the process running beneath age-related eye disease.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine has no term for macular degeneration. It reads the failing of central, detailed vision through the eye's classical relationships. The Liver is said to open into the eyes, and its Blood to moisten and brighten them. The Kidney stores the essence that sustains the eyes over a lifetime. So age-related dimming of sight is most often read as a depletion at that Liver and Kidney root. The wet form leaks new vessels under the retina and needs prompt anti-VEGF treatment. The pattern below is not a substitute for that care. The herbs are chosen to fit the pattern. An eye formula that suits a dry, deficient picture can be wrong for a damp or stagnant one.
The most common age-related picture: gradually blurring or dimming central vision, dry eyes, dizziness, tinnitus, low back and knee weakness, and vision that tires by evening. The classical direction is to nourish Liver and Kidney Yin and brighten the eyes, the pattern behind much traditional use of goji and chrysanthemum.
A heavier, foggier presentation: central blur with a sense of fullness, floaters, fatigue after eating, poor appetite, loose stools, and a pale swollen tongue with a greasy coat. The direction is to strengthen the Spleen and transform Damp so the clear Yang can rise to the eyes and the fluids stop pooling below.
This pattern is read when vision has dropped suddenly, or when there is bleeding under the retina: fixed dark spots, a dusky complexion, and a purplish tongue. The direction is to move Blood and free the collaterals. This presentation in particular needs urgent ophthalmic assessment first.
Cautions
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Beta-carotene raised lung cancer in smokers, 2.1% against 0.9% in the eye trial
In AREDS2, lung cancer occurred in 2.1% of participants taking beta-carotene versus 0.9% not taking it, and 91% of those cancers were in former smokers. This matched the earlier CARET trial, where beta-carotene plus vitamin A raised lung cancer incidence by 28% (relative risk 1.28) and total mortality by 17% in current smokers and asbestos-exposed workers, which stopped that trial early. The excess lung cancer was concentrated in current and former smokers, not never-smokers, but it is why beta-carotene was removed from the eye formula and why the lutein and zeaxanthin version is the one to choose for anyone with a smoking history.Chew et al. 2014 (AREDS2 report no. 3, secondary analyzes of lutein/zeaxanthin)Omenn GS et al., effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease (CARET)
AREDS2 slows progression; it does not restore lost sight
AREDS2 cannot bring back vision the disease has already taken, and taking it earlier or in higher doses does not change that. High-dose zinc is paired with a little copper, because zinc alone taken long term can lower copper levels.
Beta-carotene, smoking history, and the reformulated formula
Beta-carotene, the pigment in the original formula, raised lung-cancer risk in current and former smokers. The reformulated AREDS2 version substitutes lutein and zeaxanthin. These carry no such signal and matched beta-carotene for effect.
Sourcing eye and wellness herbs safely
Products sold direct to the public for eye health, weight, and general wellness have a documented history of undeclared or substituted ingredients. Species substitution is a known hazard in the herb trade. Buy from regulated suppliers and qualified practitioners who test their material, and let the pattern and a trained herbalist decide the formula.
These treatments each fit one stage of the disease, and none of them helps at every stage.
When to See Someone
Most of protecting your sight is steady and in your own hands. A few situations need a same-day or urgent eye review.
- Straight lines suddenly looking wavy or bent, a new blur or dark spot in the center of your vision, or a quick drop in vision in one eye. This can mean new wet macular degeneration and needs an urgent retina review(seek urgent care)
- A new change on a printed Amsler grid, checked one eye at a time: lines that were straight now wave, or a square goes missing. Act on any new distortion the same day(seek urgent care)
- Sudden painless loss of vision, a curtain or shadow moving across your sight, or a burst of new flashes and floaters. This can mean a retinal detachment or a blocked retinal vessel (an emergency(seek urgent care)
- A plan to start a high-dose eye supplement when you have any smoking history, worth raising before you start
- A new diagnosis of intermediate macular degeneration) the stage at which the AREDS2 formula is worth discussing with your eye specialist
- Growing difficulty with reading, faces, driving, or steps. This is the point to ask about a low-vision assessment and the rehabilitation that goes with it
Macular degeneration moves slowly for most people. The levers with the most effect are yours: not smoking, eating for your eyes, and getting seen fast if the center of your vision changes.
Common Questions
What is the difference between dry and wet macular degeneration?
The dry form is common and slow. The wet form is less common but moves faster, and it causes most of the severe sight loss from this condition. Fragile new vessels grow under the retina and leak fluid or blood. It is the one form with an urgent treatment, the anti-VEGF injection.
Should I take the AREDS2 supplement?
That is a decision for you and your retina specialist. AREDS2 is aimed at eyes already at the intermediate stage, not at healthy eyes or the earliest changes. It cannot bring back vision the disease has already taken.
Is the cheaper wet-AMD injection as good as the expensive one?
By the best test available, yes. Bevacizumab was compared head-to-head against the far pricier ranibizumab for wet AMD, and the two came out equal for vision at one year, at a fraction of the price.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 14 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.